The primary measure of ILD progression was a decline in forced vital capacity (FVC) of 5% or more between annual visits.

With this landmark complex surgery, two patients have now successfully undergone robotic lung transplants, marking a major ...

A 79-year-old man with recurrent oropharyngeal cancer has developed the first documented case of severe drug-induced interstitial lung disease following photoimmunotherapy with cetuximab-sarotalocan ...

After moving to Rotonda West, Bouyea and his wife Laura faced significant damage to their dream home due to Hurricane Ian.

Results come after positive results from a trial among people with idiopathic pulmomary disease.

The global progressive pulmonary fibrosis (PPF) treatment market is projected to be valued at USD 4,044.6 Million in 2025 and is expected to reach USD 8,182.4 Million by 2035, registering a CAGR of 7.

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell ...

Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.